Kerala Ayurveda Ltd.
Snapshot View

75.70 +2.85 ▲3.9%

27 May 2022, 04:01:00 PM
Volume: 865

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.keralaayurveda.biz
Market Cap 79.17 Cr.
Enterprise Value(EV) 145.16 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) -1.01 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-12
Industry PE 28.15 Trailing Twelve Months Ending 2021-12
Book Value / Share 2.68 Trailing Twelve Months Ending 2021-12
Price to Book Value 28.24 Calculated using Price: 75.70
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 1.06 Cr. 10,555,670 Shares
FaceValue 10
Company Profile

Kerala Ayurveda Ltd. (KAL) was founded on the banks of river Periyar at Aluva, Kochi, Kerala in 1945 by Late Vaidyan K G K Panicker, the renowned Ayurvedacharya. He was a doyen in Ayurvedic system, a visionary and a mentor. Now, more than half a century later, his inspired creation epitomizes all that is modern and state-of-the-art in Ayurveda. A leading Ayurvedic company today, KAL is backed by advanced technology and highly qualified dedicated staff.

Today Kerala Ayurveda is a major force in healthcare, growing at a spectacular rate -- with new clinics, new market strategies, new products, and new cures. Some of KAL's products are on the verge of being patented. KAL is truly on a mission to be the number one choice in Ayurveda globally.

Kerala Ayurveda has its world class manufacturing facility at Aluva, near Kochi. It also has a Herbarium.

The R&D Division of KAL has a prestigious herbal garden, which is actually a gene pool with more than 1200 species of rare and endangered medicinal plants, collected by conducting extensive surveys. These efforts also include certain hitherto unexplored tribal pockets, which are treasure groves of herbal wealth.

KAL has started its own Ayurvedic training center in view of propagating authentic Ayurveda. The training center, called KAL HRD CENTER is functioning as an annex to KAL Ayurveda Hospital at Aluva, near Kochi in Kerala. The center is easily assessable since it is located about 10 km, from the Nedumbassery International Airport (Cochin).The center is well equipped and conducts various training programme, various training Programs related with Ayurveda are offered by KAL HRD Center.

Publication Division- KAL has set up a publication division to publish Ayurvedic materials. An Ayurvedic quarterly journal named and styled as KAL VAIDYAM is published by this division. The division is designed to publish books, audio and video CDs and tapes on Ayurveda for the public and the scientific community.

Different offerings of the company:

  • Classical Medicines- These are formulations manufactured based on the Ayurvedic Formulatory of India. This is developed from 3000 years old scriptures. In KAL they  follow the traditional method for manufacturing these products.
  • Proprietary Medicines- These medicines are manufactured based on the formulas developed by KAL R&D division. The products are clinically tested by clinical trial, animal trial, etc before being launched in the market.
  • Katrasoft- Katrasoft is the technology division of Katra group, a multinational company with diverse business intrests in over 15 domains and investments in over 20 companies. Katrasoft operates as a division of Kerala Ayurveda Limited, one of the oldest names in Ayurveda, which is a listed company owned by Katra group.
  • Katra Nursing- Katra Nursing, one of the divisions of Katra Healtcare Pvt.Ltd. is a fast growing healthcare organization centered in Bangalore, India focussed in the training program of CGFNS, NCLEX and IELTS. The primary objective of the organization is to be a one-stop solution provider for nursing fraternity by exploring the best opportunities availble for KAL's nurses.

Achievements/ recognition:

KAL Hospital, Aluva has been accredited with “Green Leaf” certification by Department of Tourism, Government of Kerala, which is the highest classification for outstanding quality of facilities and services.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+3.91%
1 Week
+2.23%
1 Month
+2.37%
3 Month
+12.82%
6 Month
+8.84%
1 Year
+44.74%
2 Year
+70.88%
5 Year
-12.08%
10 Year
+89.25%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 862.54 38.72 43.39 93.90 -183.04
Return on Capital Employed (%) 2.39 5.38 8.35 9.15 8.91 8.88 7.64 9.27 -0.45
Return on Assets (%) -0.92 1.47 3.72 3.81 4.27 3.14 2.59 4.15 -4.47

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds -11 -10 -9 -6 7 8 4 8 3 3
Non Curr. Liab. 58 51 53 53 24 48 59 63 74 76
Curr. Liab. 13 23 25 24 48 45 28 31 34 31
Minority Int. 1 1 1 1 1 2 2 2 2 2
Equity & Liab. 61 64 71 73 81 103 92 103 114 112
Non Curr. Assets 51 55 57 59 59 61 64 67 67 72
Curr. Assets 9 9 14 14 22 42 28 33 44 41
Misc. Exp. not W/O 0 3 3
Total Assets 61 64 71 73 81 103 92 103 114 112

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales 31 35 39 46 50 56 62 77 62 72
Other Income 0 1 0 1 0 0 1 0 0 0
Total Income 31 35 39 46 51 56 63 77 62 73
Total Expenditure -28 -32 -33 -39 -43 -48 -57 -69 -61 -66
PBIDT 3 4 6 8 7 8 5 7 1 6
Interest -1 -1 -2 -2 -1 -2 -3 -2 -6 -7
Depreciation -2 -1 -1 -2 -2 -2 -1 -1 -1 -1
Taxation -1 -1 -1 -1 -1 -1 -1 0 2
Exceptional Items 0 0 1 1
PAT 0 1 3 3 3 3 3 4 -5 -1
Minority Interest 0 0 0 0 0 0 0 0 0
Share Associate
Other Related Items
Consolidated Net Profit -1 1 2 3 3 3 2 4 -5 -1
Adjusted EPS -1 1 2 3 3 3 2 4 -5 -1

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 9 -8 0 0 6 4 -10 12 5 7
Cash Fr. Inv. -1 -4 -1 0 -3 -3 -3 -3 -4 -1
Cash Fr. Finan. -11 11 1 2 -3 0 17 -12 1 6
Net Change -3 0 -1 2 0 1 4 -2 2 12
Cash & Cash Eqvt 1 1 1 2 2 3 7 5 6 19

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 61.52 61.52 61.52 61.52 61.52 61.52 61.52 61.52 61.52
Public 38.48 38.48 38.48 38.48 38.48 38.48 38.48 38.48 38.48
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00

Announcements View Details

Mon, 23 May 2022
Board Meeting Intimation for Board Meeting For Consideration And Approval Of Audited Financials For The Quarter And Year Ended 31St March 2022
KERALA AYURVEDA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 inter alia to consider and approve Board meeting for consideration and approval of Audited Financials for the quarter and year ended 31st March 2022
Tue, 26 Apr 2022
Compliance Under Regulation 40(10) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Compliance under Regulation 40(10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
Wed, 13 Apr 2022
Confirmation Pertaining To Non-Applicability Of SEBI Circular Dated November 26 2018 Pertaining To Fund Raising By Issuance Of Debt Securities By Large Entities (Annual Disclosure)
Confirmation pertaining to non-applicability of SEBI Circular dated November 26 2018 pertaining to fund raising by issuance of debt securities by large entities (Annual Disclosure)

Technical Scans View Details

Fri, 27 May 2022
High Delivery Percentage High Delivery Percentage
Opening at Low Opening at Low
Close Within 52 Week High Zone Close Within 52 Week High Zone
Close Entering 52 Week High Zone Close Entering 52 Week High Zone
High Increase 3 Months High Increase 3 Months

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 216,539.98 902.50 +0.2%
Divi's Laboratories Ltd. 93,297.61 3,514.45 +1.9%
Cipla Ltd. 77,954.36 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. 73,094.23 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. 55,313.96 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. 49,744.83 2,939.85 +1.3%
Gland Pharma Ltd. 47,677.82 2,897.00 +1.5%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 33.60 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2022-03 31.51 3,514.45 +1.9%
Cipla Ltd. Consolidated 2022-03 30.97 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 33.49 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 52.40 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 64.02 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2022-03 39.35 2,897.00 +1.5%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.19 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2022-03 7.95 3,514.45 +1.9%
Cipla Ltd. Consolidated 2022-03 3.74 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.80 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 9.81 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8.36 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2022-03 6.66 2,897.00 +1.5%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 3,514.45 +1.9%
Cipla Ltd. Consolidated 2021-03 0.10 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 0.84 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2021-03 0.00 2,897.00 +1.5%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,514.45 +1.9%
Cipla Ltd. Consolidated 2021-03 14.13 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,897.00 +1.5%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,514.45 +1.9%
Cipla Ltd. Consolidated 2021-03 14.13 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,897.00 +1.5%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 3,514.45 +1.9%
Cipla Ltd. Consolidated 2021-03 19,159.59 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 8,004.83 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 2,897.00 +1.5%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 3,514.45 +1.9%
Cipla Ltd. Consolidated 2021-03 2,401.30 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 1,251.88 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2021-03 996.96 2,897.00 +1.5%